Mitotic kinesin inhibitors

An alkyl group selected technology, applied in the field of fluorinated 2-aminomethylthienopyrimidinone compounds, can solve problems such as limited applicability

Inactive Publication Date: 2008-01-16
MERCK & CO INC
View PDF114 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Because these drugs do not specifically target the mitotic spindle, they have side effects that limit their applicability

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mitotic kinesin inhibitors
  • Mitotic kinesin inhibitors
  • Mitotic kinesin inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0435] The examples provided are intended to assist in further understanding of the invention. The particular materials, substances and conditions employed are intended to be illustrative of the invention and not to limit the fair scope of the invention.

[0436] Flowchart 1

[0437]

[0438] Flowchart 1 (continued)

[0439]

[0440] Step 1: 2-[(3-Methylbutyryl)amino]thiophene-3-carboxylic acid (1-2)

[0441] 2-Aminothiophene-3-carboxylic acid methyl ester at 0°C 1-1 (5.0 g, 31.8 mmol) in DMF (30 mL) was added isovaleryl chloride (4.21 g, 34.9 mmol). The reaction was stirred at 0 °C for 2.5 h, then extracted with ether and washed with water. The organic solution was dried over sodium sulfate, filtered and concentrated to give the amide as an oil. To a solution of methyl 2-[(3-methylbutyryl)amino]thiophene-3-carboxylate (7.60 g, 31.49 mmol) in THF / MeOH was added 1 N KOH (2.65 g, 47.24 mmol) and the reaction was stirred overnight. The reaction was neutralized ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to fluorinated 2-aminomethylthienopyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

Description

Background of the invention [0001] The present invention relates to fluorinated 2-aminomethylthienopyrimidinone compounds which are inhibitors of mitotic kinesins, in particular inhibitors of mitotic kinesins KSP, useful in the treatment of cell proliferative diseases such as cancer, hyperplasia, restenosis, cardiac Hypertrophy, immune disorders and inflammation. [0002] Therapeutic agents used in the treatment of cancer include taxanes and vinca alkaloids. Taxanes and vinca alkaloids act on microtubules, which are present in various cellular structures. Microtubules are the major structural elements of the mitotic spindle. The mitotic spindle is responsible for distributing the replication template for the genome into each of the two daughter cells produced by cell division. It is speculated that the mitotic spindle is disrupted by these drugs, thereby inhibiting cancer cell division and inducing cancer cell death. However, microtubules form other types of cellular struc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D495/04A61K31/513A61P35/00C07D333/36C07D333/38
CPCC07D495/04A61P35/00A61P43/00
Inventor P·J·科尔曼G·D·哈特曼
Owner MERCK & CO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap